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Objectives. Mechanisms inﬂuencing the course of physical and mental functioning after an atherosclerotic event are unclear. We
examined eﬀects of white matter lesion (WML) activity on changes in functioning in patients with symptomatic atherosclerotic
disease. Methods. In 486 patients (58 ± 9 years) of the Second Manifestations of ARTerial disease-Magnetic Resonance (SMART-
MR)study,volumetricWMLmeasurementson1.5TMRIwereperformedatbaselineand3.9±0.4yearsfollowup.Functioningwas
assessed with the modiﬁed Short-Form 12 (SF-12) questionnaire. Associations of WML progression with changes in functioning
were adjusted for age, sex, and vascular risk factors. Results. Physical functioning (baseline: 44, 10th–90th percentile 29–55)
improved, whereas mental functioning (baseline: 51, 10th–90th percentile 32–60) declined during followup. WML progression
(highest quartile versus rest) contributed to a stronger decline in mental functioning (B =− 1.76, 95% CI −3.11 to −0.42), but
did not inﬂuence changes in physical functioning. Conclusions. Progression of WML volume contributes to a decline in mental
functioning in patients with symptomatic atherosclerotic disease.
1.Introduction
Ischemic heart disease and stroke are leading causes of
disability and mortality worldwide [1]. As a result of
improved survival and the lifelong aspect of these diseases,
health-related quality of life (HRQoL), including physical
and mental functioning, has become an increasingly impor-
tant clinical and research outcome when evaluating burden
of disease and treatment beneﬁts. In addition, reduced
physical and mental functioning not only interferes with
daily living, but also increases the risk of incident ischemic
vasculareventsandmortality[2–4].Comparedtothegeneral
population, HRQoL is substantially lower in patients with
ischemic heart disease and stroke, especially in the domain
of physical functioning [5–7]. A recent study indicated that
HRQoL not only is lower in the acute phase of recovery
from stroke, but also can decline up to ﬁve years after stroke
in survivors free of recurrence or myocardial infarction [8].
Also, marked impairments in HRQoL have been observed in
patients with other manifestations of atherosclerotic disease,
including peripheral arterial disease [9, 10] and abdominal
aortic aneurysm [11, 12].
Patients with symptomatic vascular disease frequently
have atherosclerotic changes in the small vasculature in
the brain, which are characterized by white matter lesions
(WMLs) on magnetic resonance imaging (MRI) [13]. Al-
though WMLs are often asymptomatic, they have been iden-
tiﬁed as a risk factor for functional decline [14], late-life
depression[15,16],andcognitiveimpairment[17–19].Ithas
been suggested that greater disease activity, characterized by
an accelerated progression of WML volume, is an important2 Journal of Aging Research
underlying mechanism contributing to this elevated risk
[20, 21], but longitudinal studies are still relatively scarce.
Whether greater progression of WML volume is also associ-
atedwithapoorerHRQoLhasnotbeenstudiedyet,although
itcouldbeexpectedthatmoresubtleimpairmentsinphysical
and mental functioning could already be present in patients
withgreaterWMLdiseaseactivity,beforethedevelopmentof
depression or functional decline. In addition, it is unknown
whether the inﬂuence of WML progression on physical
and mental functioning is comparable between patients
with diﬀerent locations of symptomatic atherosclerotic
disease.
Our ﬁrst aim was to investigate the course of physical
and mental functioning in patients with diﬀerent manifes-
tations of atherosclerotic disease over four years of follow-
up. Second, we examined whether greater progression of
WML volume contributed to poorer physical and mental
functioning in these patients and whether these associations
depended on the location of symptomatic atherosclerotic
disease.
2.MaterialsandMethods
2.1. Participants. Data were used from the Second Manifes-
tations of ARTerial disease-Magnetic Resonance (SMART-
MR) study, a prospective cohort study aimed to investigate
brain changes on MRI in 1309 independently living patients
with symptomatic atherosclerotic disease. Details of the
design and participants have been described elsewhere [13].
For the current study, data were used from 989 patients
newly referred to the University Medical Center Utrecht
between January 2002 and December 2005 with manifest
peripheral arterial disease, coronary artery disease, cere-
brovascular disease, or abdominal aortic aneurysm without
MR contraindications and available data on the HRQoL
questionnaire. During a 1-day visit to our medical center,
an MRI of the brain, physical examination, blood, and urine
sampling were performed. Risk factors, medical history, and
functioning were assessed with questionnaires.
Between January 2006 and May 2009, all participants
stillalivewereinvitedforfollow-upmeasurements,including
MRI of the brain, neuropsychological testing, a physi-
cal examination, blood and urine sampling, risk factors,
medical history, and functioning. The SMART-MR study
was approved by the ethics committee of our institu-
tion, and written informed consent was obtained from all
participants.
In total, 585 of the surviving cohort (62% of n = 943)
gave written informed consent; 346 (37%) persons refused,
and 12 (1%) were lost to followup.
2.2.MagneticResonanceImagingProtocol. MRinvestigations
were performed on a 1.5-tesla whole-body system (Gyroscan
ACS-NT, Philips Medical Systems, Best, The Netherlands).
The protocol consisted of a transversal T1-weighted gradi-
ent-echo sequence (repetition time (TR)/echo time (TE):
235/2ms; ﬂip angle, 80◦), a transversal T2-weighted turbo
spin-echo sequence (TR/TE: 2200/11ms and 2200/100ms;
turbo factor 12), a transversal T2-weighted ﬂuid attenuating
inverse recovery (FLAIR) sequence (TR/TE/inversion time
(TI): 6000/100/2000ms), and a transversal inversion recov-
ery (IR) sequence (TR/TE/TI: 2900/22/410ms) (ﬁeld of view
230×230mm;matrixsize,180×256;slicethickness,4.0mm;
no gap; 38 slices).
2.3. Brain Segmentation. We used the T1-weighted gradient
echo, IR sequence, and FLAIR sequence for brain segmen-
tation. The probabilistic segmentation technique has been
described elsewhere [22, 23]. The segmentation program
distinguishes cortical gray matter, white matter, sulcal and
ventricularcerebrospinalﬂuid(CSF),andlesions.Theresults
of the segmentation analysis were visually checked for the
presence of infarcts and adapted if necessary to make a
distinction between WML and infarct volumes. Total brain
volume was calculated by summing the volumes of gray
and white matter and, if present, the volumes of WML
and infarcts. All volumes cranial to the foramen magnum
were included. As a result, the total brain volume includes
the cerebrum, brainstem, and cerebellum. Total intracranial
volume (ICV) was calculated by summing the total brain
volume and the volumes of the sulcal and ventricular
CSF.
2.4. Infarcts and White Matter Lesions. The whole brain
was visually searched for infarcts by a trained investigator
and a neuroradiologist. Raters were blinded to history
and diagnosis of the patient. Discrepancies in rating were
reevaluated in a consensus meeting. Infarcts were deﬁned
as focal hyperintensities on T2-weighted images of at least
3mm in diameter. Hyperintensities located in the white
matter also had to be hypointense on T1-weighted and
FLAIR images in order to distinguish them from WML.
Dilated perivascular spaces were distinguished from infarcts
onthebasisoftheirlocation,form,andtheabsenceofgliosis.
Thelocation,aﬀected ﬂow territory, and type were scored for
every infarct.
WML volumes obtained with the segmentation program
were summed to obtain total WML volume. Volumes of
WML were normalized for ICV and expressed as percentage
of ICV.
2.5. Physical and Mental Functioning. At baseline and fol-
lowup, patients completed the Short Form-12 (SF-12) [24],
a shortened version of the Short Form-36 (SF-36) Medical
Outcomes Study Health Survey [25], to measure HRQoL
at baseline and followup. The SF-12 questionnaire includes
1 or 2 items from each of the 8 health summary scales of
the SF-36 [26] and enables calculation of the Physical (PCS)
and Mental Component Summary scales (MCS). The SF-12
summary scales are positively scored and normalized to a
general population mean of 50 with standard deviation of
10. Higher SF-12 scores indicate better HRQoL; a positive
change in SF-12 scores indicates an improvement, and a
negative change a deterioration in HRQoL. Because of its
brevity, the SF-12 is considered advantageous over the SF-
36 for large studies focusing on overall physical and mental
functioning [26].Journal of Aging Research 3
2.6. Severity of Atherosclerotic Disease at Baseline. In patients
with peripheral arterial disease, severity of vascular disease
at baseline was assessed using the Fontaine scale [27]. Stage
1 (pain-free walking distance >200m) and stage 2 (pain-
free walking distance <200m) were deﬁned as mild or
moderate ischaemia, whereas stage 3 (rest pain) and stage 4
(ulceration or gangrene) were deﬁned as severe ischaemia.
In patients with coronary artery disease, disease severity
was rated according to the number of coronary arteries
with marked atherosclerosis (>70% stenosis or fractional
ﬂow reserve <0.80 or treatment of the vessel). One-vessel,
two-vessel, three-vessel, left main disease with or without
right coronary artery involvement was rated in all coronary
artery disease patients on the basis of coronary angiography
reports. Information was incomplete in some patients, and
additional information was obtained from percutaneous
coronary intervention or coronary artery bypass grafting
reports. For patients with cerebrovascular disease, disease
severity was classiﬁed with a handicap scale, the modiﬁed
Rankin Scale (mRS) [28].
2.7. Other Variables. During the visit to the medical center,
anovernight fasting venousblood sample wastaken to deter-
mine glucose levels. Systolic and diastolic blood pressures
(mmHg) were measured twice with a sphygmomanometer
and averaged. Hypertension was deﬁned as mean systolic
blood pressure ≥160mmHg, mean diastolic blood pressure
≥95mmHg, or self-reported antihypertensive drug use. Dia-
betes mellitus was deﬁned as fasting glucose ≥7.0mmol/L
or self-reported use of oral antidiabetic drugs or insulin.
Smoking habits and alcohol intake were assessed with
questionnaires. Packyears of smoking was calculated, and
alcohol use was categorized into never, past, and current.
2.8. Study Sample. Of the 585 patients participating at
followup, data on baseline or follow-up MRI variables were
missing in 74 patients (no MR (n = 41), irretrievable MR
data (n = 5), missing FLAIR images (n = 7), or artefacts
(n = 21)). Of these, HRQoL data at followup were missing
in 17 patients. Of these 494 patients, data on vascular risk
factors were missing in 8 patients. This resulted in a total
study sample of 486 patients.
Compared to patients who were lost to followup (n =
503), patients who participated at followup (n = 486)
were signiﬁcantly younger (mean 57.5 versus 59.6 years) at
baseline, had less often hypertension (50% versus 57%) and
diabetes mellitus (16% versus 25%), more often reported
current alcohol intake (79% versus 72%), had lower WML
volume (median 1.3 versus 1.7mL), had better mental
functioning (median 51.0 versus 48.3), and were less often
included with peripheral arterial disease (19% versus 26%)
or abdominal aortic aneurysm (5% versus 11%) (Table 1).
2.9. Data Analysis. First, we calculated changes in physical
and mental functioning after on average 4 years of fol-
lowup in the total sample and then compared changes in
physical and mental functioning between diﬀerent locations
of symptomatic atherosclerotic disease using generalized
Table 1: Baseline characteristics of patients with complete data at
followup and of those lost to followup.
Complete data at
followup
(n = 486)
Lost to followup
(n = 503)
Age (years) 58 ± 9.3 60 ± 10.2
Male gender (%) 80 79
Diagnosis of symptomatic
atherosclerotic disease‡
(i) Peripheral arterial
disease 19 26
(ii) Coronary artery
disease 65 61
(iii) Cerebrovascular
disease 24 23
(iv) Abdominal aortic
aneurysm 51 1
Severe atherosclerotic disease£ 11 9
Smoking† (pack/years) 21 (0–53) 18 (0–50)
Alcohol use
(i) Never 13 18
(ii) Former 7 11
(iii) Current 79 72
Hypertension (%) 50 57
Diabetes mellitus (%) 16 25
Total intracranial volume
(mL) 1467 ± 127 1457 ± 132
Absolute total WML volume†
(mL) 1.3 (0.4–5.8) 1.7 (0.6–8.3)
Physical functioning† 44 (29–55) 43 (26–54)
Mental functioning† 51 (32–60) 48 (29–60)
WML: white matter lesions; mRS: modiﬁed Rankin Scale.
‡ The diﬀerent groups of symptomatic atherosclerotic disease do not add up
to the total study sample of 486, because various locations of symptomatic
atherosclerotic disease can occur within one patient.
£Deﬁned as patients with coronary artery disease and three-vessel or left
main disease at inclusion, patients with cerebrovascular disease and a mRS
grade ≥2 at inclusion, or patients with peripheral arterial disease with
Fontaine grade ≥3 at inclusion.
Mean ± SD
† Median, (10th–90th percentile).
linear models with physical and mental functioning scores at
followup as the dependent variables and location of symp-
tomatic atherosclerotic disease, age, sex, baseline physical
or mental functioning, and follow-up time as independent
variables.
Second, linear regression analysis was used to investigate
whether greater progression of WML volume was associated
with changes in physical and mental functioning. Progres-
sion of WML volume was deﬁned as the diﬀerence in WML
volume (% of ICV) between baseline and followup. We
divided WML progression into quartiles, and dichotomized
WML progression (highest quartile (n = 126) versus lower
quartiles (n = 360) to investigate whether patients with
greatest progression showed a diﬀerent course of physical4 Journal of Aging Research
Table 2: Baseline characteristics.
Total sample
(n = 486)
Peripheral arterial
disease (n = 90)‡
Coronary artery
disease (n = 318)‡
Cerebrovascular
disease (n = 115)‡
Abdominal aortic
aneurysm (n = 26)‡
Age (years) 58 ± 9.3 56 ± 10.2 58 ± 9.0 59 ± 9.9 62 ± 7.9
M a l e g e n d e r ( % ) 8 06 68 67 69 6
Smoking†
(pack/years) 21 (0–53) 26 (1–56) 18 (0–51) 22 (0–53) 32 (7–76)
Alcohol use
(i) Never 13 16 12 15 8
( i i ) F o r m e r 71 08 4 4
(iii) Current 79 74 80 82 89
H y p e r t e n s i o n ( % ) 5 05 84 76 15 4
Diabetes mellitus
(%) 16 17 16 18 27
Total intracranial
volume (mL) 1467 ± 127 1437 ± 132 1474 ± 123 1467 ± 128 1507 ± 125
Absolute total
WML volume†
(mL)
1.3 (0.4–5.8) 1.4 (0.5–4.6) 1.3 (0.3–4.7) 2.2 (0.4–11.2) 1.8 (0.5–10.3)
Physical
functioning† 44 (29–55) 40 (20–53) 44 (31–55) 46 (31–56) 43 (32–55)
Mental
functioning† 51 (32–60) 50 (33–60) 51 (31–60) 51 (34–59) 52 (34–58)
WML: white matter lesions.
‡The diﬀerent groups of symptomatic atherosclerotic disease do not add up to the total study sample of 486, because various locations of symptomatic
atherosclerotic disease can occur within one patient.
Mean ± SD
† Median, (10th–90th percentile).
and mental functioning than patients with no or minimal
WML progression. Analyses were ﬁrst performed in the
total sample, and because we expected that associations
could be inﬂuenced by the type of underlying atherosclerotic
disease, we repeated the analyses within strata of locations
of atherosclerotic disease. In model I, associations were
adjusted for age, sex, baseline physical or mental functioning
and follow-up time. We additionally adjusted for smoking,
alcohol use, hypertension, and diabetes mellitus in model
II, because it is not clear to what extent these vascular risk
factors are confounders or preceding factors in the pathway
between WML volume and functioning, or both.
We repeated the analyses after excluding patients with
severe atherosclerotic disease at baseline, deﬁned as patients
with coronary artery disease and three-vessel or left main
disease at inclusion, patients with cerebrovascular disease
and a mRS grade ≥2 at inclusion, or patients with peripheral
arterial disease with Fontaine grade ≥3 at inclusion. This
was done to assess to what extent the observed associations
between small-vessel disease and functioning were inﬂu-
enced by the severity of macrovascular disease.
Further, to examine whether associations were indepen-
dent of incident vascular events during followup, analyses
were repeated after excluding patients who experienced a
new vascular complication (nonfatal ischemic stroke or
myocardial infarction) between baseline and followup. In all
analyses, 95% conﬁdence intervals are given. SPSS version
15.0 (Chicago, Ill, USA) was used to analyze our data.
3. Results
Baseline characteristics are summarized in Table 2.M e a na g e
of the study population was 58 ± 9 years, and 80% was male.
At baseline, median physical functioning was 44 (10–90th
percentile 29–55) and mental functioning was 51 (10–90th
percentile 32–60).
Mean elapsed time between the vascular event and
screening date was 2.1 ± 1.4 months. In the total sample,
physical functioning improved (median 3.8, 10th–90th per-
centile −6.5 to 18.3) and mental functioning deteriorated
(median −4.0, 10th–90th percentile −14.0 to 13.0) after a
meanfollowupof3.9 ±0.4y ears.W hendiﬀerentlocationsof
atherosclerotic disease were identiﬁed, physical functioning
improved in all groups (Figure 1). This improvement was
signiﬁcantly lower in patients with cerebrovascular disease
compared to patients with other locations of symptomatic
atherosclerotic disease (B =− 2.58, 95% CI −4.29 to −0.87).
Mental functioning deteriorated in all groups, without
any signiﬁcant diﬀerences between diﬀerent locations of
symptomatic atherosclerotic disease (Figure 1).
3.1. Progression of WML Volume. Patients with greatest pro-
gression of WML volume (highest quartile, >0.07% increase
in WML volume as % of ICV) showed a signiﬁcantly
stronger deterioration in mental functioning than patients
with lower WML progression (B =− 1.76, 95% CI −3.11
to −0.42, Figure 2) in model I. Additional adjustmentJournal of Aging Research 5
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Figure 1: Mean changes in physical and mental functioning
for diﬀerent locations of symptomatic atherosclerotic disease,
adjusted for age, sex, baseline functioning, and follow-up time.
Signiﬁcantdiﬀerences,comparedtootherlocationsofsymptomatic
atherosclerotic disease, are indicated with an asterix.
−6
−4
−2
0
2
4
6
M
e
a
n
c
h
a
n
g
e
i
n
f
u
n
c
t
i
o
n
i
n
g
Physical functioning Mental functioning
∗
Highest quartile of WML progression
Lower quartiles of WML progression
Figure 2: Mean changes in physical and mental functioning for
patients with greatest progression of white matter lesion (WML)
volume (highest quartile, >0.07% increase in WML volume as %
of ICV) versus patients in the lower three quartiles of progression,
adjusted for age, sex, baseline functioning, and follow-up time.
Signiﬁcant diﬀerences are indicated with an asterix.
for vascular risk factors did not change the results (data
not shown). When analyses were repeated within diﬀerent
strata of locations of symptomatic atherosclerotic disease,
greater WML progression was associated with a stronger
deterioration in mental functioning in all patients except
forpatientswithcerebrovasculardisease(Figure 3),although
the deterioration was statistically signiﬁcant only in patients
with coronary artery disease (model I, B =− 2.03, 95%
CI −3.61 to −0.45). Additional adjustment for vascular risk
factors did not change these associations.
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Figure 3: Mean changes in mental functioning for patients with
greatest progression of white matter lesion (WML) volume versus
patients in the lower three quartiles of progression, for diﬀerent
locations of symptomatic atherosclerotic disease, adjusted for
age, sex, baseline functioning, and follow-up time. Signiﬁcant
diﬀerences are indicated with an asterix.
Greater progression of WML volume was not signiﬁ-
cantly associated with changes in physical functioning at
followup in model I in the total sample (B =− 0.04, 95%
CI −1.79 to 1.72, Figure 2) or within strata of patients with
coronary artery disease (B = 0.02, 95% CI −2.26 to 2.30),
peripheral arterial disease (B = 1.26, 95% CI −3.65 to 6.16),
cerebrovascular disease (B = 0.00, 95% CI −3.46 to 3.46),
or abdominal aortic aneurysm (B =− 0.38, 95% CI −7.07 to
6.32).
Excluding patients with most severe symptomatic
atherosclerotic disease (n = 46) did not materially change
the results. Greater WML progression was still signiﬁcantly
associated with a stronger deterioration in mental function-
ing (model I, B =− 1.82, 95%−3.25 to −0.38).
Between baseline and followup, 17 patients experienced
a nonfatal vascular event. Excluding these patients did not
change the observed associations of greater WML progres-
sion with a stronger deterioration in mental functioning
(model I, B =− 1.83, 95% CI −3.20 to −0.46).
4. Discussion
In a cohort of patients with diﬀerent manifestations of
symptomatic atherosclerotic disease, physical functioning
substantially improved in all patients after four years of
followup, although the improvement was less in patients
with cerebrovascular disease. Mental functioning declined
in all types of symptomatic atherosclerotic disease. Greater
progression of WML volume over four years of followup was
associated with a stronger decline in mental functioning in
all patients except for those with cerebrovascular disease.6 Journal of Aging Research
To our knowledge, this is the ﬁrst study directly investi-
gating the inﬂuence of WML progression on the course of
physical and mental functioning in patients with diﬀerent
manifestations of symptomatic atherosclerotic disease. A
strength of this study is that by including patients with
diﬀerent locations of symptomatic atherosclerotic disease we
could investigate whether the eﬀect of WML progression on
physical and mental functioning depended on the type of
underlying vascular disease. Furthermore, volumetric WML
assessment provided estimates that are more precise and
less inﬂuenced by observer bias than visual rating scales
[29–31] and enabled the measurement of relatively small
volume changes over time. In addition, we included a large
number of patients, and the extensive information available
on cardiovascular risk factors and the extent of clinical and
subclinical atherosclerosis made it possible to adjust for
potential confounders.
A limitation of this study is that, despite the large sample
size, relatively few patients had peripheral arterial disease,
cerebrovascular disease, or abdominal aortic aneurysm.
Although similar associations were found in patients with
coronary artery disease, peripheral arterial disease and
abdominal aortic aneurysm, the relatively low number of
patients with locations of symptomatic atherosclerotic dis-
ease other than coronary artery disease contributed to large
conﬁdence intervals and possibly nonsigniﬁcant relations
in these patients. Further, the largest impact on physical
and mental functioning would be expected in patients
suﬀering most severe atherosclerotic events. Because these
patients are less likely to participate in our study, this
could have contributed to a relative underestimation of the
eﬀect. Moreover, patients who participated at followup were
healthier at baseline, with fewer vascular risk factors, lower
WML volume, and higher mental functioning than patients
lost to followup. Therefore, the changes in physical and
mental functioning might have been less prominent in the
total cohort. Also, because baseline mental functioning was
higher in patients with complete data at followup, regression
to the mean could have contributed to the observed decline
in mental functioning after four years. On the other hand,
the selection of relatively healthy patients could have resulted
in a decreased contrast between those with greatest WML
progression and those without, which could have led to
an underestimation of the eﬀect of WML progression on
changes in mental functioning.
In recent years, HRQoL has become an increasingly
importantclinicalandresearchoutcomemeasurewheneval-
uating burden of disease and treatment beneﬁts in patients
with atherosclerotic disease. Population-based studies have
shown that patients with various manifestations of symp-
tomatic atherosclerotic disease have a poorer HRQoL com-
pared to the general population, with most pronounced
eﬀects on physical functioning [5–7, 9, 10]. It is unclear
whether physical and mental functioning returns to pop-
ulation levels after the acute phase of recovery or whether
functioning remains lower, or perhaps even further declines
after the initial event.
Our data showed that physical functioning was sub-
stantially lower in patients with symptomatic atherosclerotic
disease in the acute phase of recovery from an atheroscle-
rotic event compared to previously published age-adjusted
population norms [32]. In a previous population-based
study, a prolonged decline in HRQoL was observed in stroke
survivors free from recurrent stroke or myocardial infarc-
tion [8]. Although we found an improvement in physical
functioning in our sample of patients with cerebrovascular
disease after four years followup, this improvement was
substantiallylowercomparedtopatientswithotherlocations
of symptomatic atherosclerotic disease. In line with our ﬁnd-
ings, another study also reported signiﬁcant improvements
in functioning in postoperative abdominal aortic aneurysm
patients, which returned to population norms in long-term
survivors [11].
In our study, mental functioning was similar to pop-
ulation norms in the acute phase of recovery from a
vascular event, but declined during a four year follow-up
period. Other studies reported an increased prevalence of
mood disturbances already in the acute phase in patients
hospitalized for ischemic cardiac or cerebrovascular events
[33, 34]. One explanation for our ﬁndings could be that
in the acute phase of an atherosclerotic event, subjective
well-being is dominated by the substantial impairments in
physical functioning, whereas awareness of the emotional
consequences arises after recovery of physical functioning.
Analternative explanation couldbe thatthe courseof mental
functioning in patients with symptomatic atherosclerotic
disease depends on the severity of the atherosclerotic
event. Relatively few patients were included with severe
atherosclerotic disease in our study, which could contribute
to the diﬀerent ﬁndings in the course of mental functioning
between our study and others.
The underlying mechanisms contributing to a lower
HRQoL in patients with symptomatic atherosclerotic disease
are unclear. It has been suggested that a lower HRQoL could
result from direct complications of the disease or treatment
of underlying vascular risk factors, or from raised awareness
of the disease [35]. An alternative mechanism contributing
t oal o w e rp e r c e i v e dH R Q o Lc o u l db et h ep r e s e n c eo fc o -
occurring intracerebral atherosclerotic changes, character-
ized by WMLs on MRI. WMLs are strongly associated with
the presence of common vascular risk factors, including
increased age, hypertension, and diabetes mellitus [36–38].
Although the exact underlying pathophysiological mecha-
nismsremainunclear,arterioscleroticchangestothecerebral
small vasculature, with consequent ischemia, apoptosis, and
blood-brain barrier alterations, are thought to be involved
in the formation and progression of WMLs [39]. Although
WMLs are often asymptomatic MRI ﬁndings, increased
volume and progression of WML have been previously
associated with an increased risk of functional decline [14],
depression [16], and cognitive impairment [18, 19]. WMLs
are thought to account for the increased risks of functional
decline and mood disorders by disrupting brain pathways
that are involved in the regulation of physical and emotional
responses [40]. Although we did not formally measure
depression, our ﬁnding that increased WML activity was
associated with a greater decline in mental functioning
may be interpreted as being supportive of this “vascularJournal of Aging Research 7
depression” hypothesis [40]. Greater progression of WML
volumecontributedtoastrongerdeclineinmentalfunction-
ing in all patients except for patients with cerebrovascular
disease. This ﬁnding is somewhat counterintuitive but may
be explained by our ﬁnding of little improvement in physical
functioning in patients with cerebrovascular disease. It could
be that as a result of the substantial impairments and
disability already associated with stroke lesions, increased
progression of WML volume does not substantially con-
tribute to the decline in mental functioning in these patients.
5. Conclusion
In summary, in patients with diﬀerent manifestations of
atherosclerotic disease, we found that physical functioning
was mainly impaired in the acute phase after a symptomatic
atherosclerotic event and improved during four years of
followup, although improvement in physical functioning
remainedsubstantiallylowerinpatientswithcerebrovascular
disease. Mental functioning was relatively unimpaired in the
early phase, but declined in the four years thereafter. Greater
progression of WML volume contributed to an even stronger
decline in mental functioning in patients with symptomatic
atherosclerotic disease. Considering the substantial impact
on well-being and previously reported increased risk of
adverse events associated with lower mental and physical
functioning, further research should investigate whether
modiﬁcation of WML through better control of vascular risk
factors could inﬂuence the course of HRQoL in patients with
symptomatic atherosclerotic disease.
Conﬂict of Interests
The authors report no conﬂict of interests.
Acknowledgments
The authors gratefully acknowledge the members of the
SMART Study Group of UMC Utrecht: A. Algra, M.D.,
Ph.D., Julius Center for Health Sciences and Primary Care
and Rudolf Magnus Institute for Neurosciences, Department
of Neurology; P. A. Doevendans, M.D., Ph.D., Department
of Cardiology; D. E. Grobbee, M.D., Ph.D. and G. E. H. M.
Rutten, M.D., Ph.D., Julius Center for Health Sciences and
Primary Care; L. J. Kappelle, M.D., Ph.D., Department of
Neurology; F. L. Moll, M.D., Ph.D., Department of Vascular
Surgery; F. L. J. Visseren, M.D., Ph.D., Department of
Vascular Medicine. This study was supported by a program
grant from the Netherlands Heart Foundation (NHF: project
no. 2007B027). The NHF had no involvement in study
design; in the collection, analysis, and interpretation of data;
in writing of the report; in the decision to submit paper for
publication.
References
[1] A. D. Lopez and C. D. Mathers, “Measuring the global burden
ofdiseaseandepidemiologicaltransitions:2002–2030,”Annals
of Tropical Medicine and Parasitology, vol. 100, no. 5-6, pp.
481–499, 2006.
[2] E. L. Idler and Y. Benyamini, “Self-rated health and mortality:
a review of twenty-seven community studies,” Journal of
Health and Social Behavior, vol. 38, no. 1, pp. 21–37, 1997.
[ 3 ]P .K .M y i n t ,R .N .L u b e n ,P .G .S u r t e e se ta l . ,“ S e l f - r e p o r t e d
mental health-related quality of life and mortality in men
and women in the European Prospective Investigation into
Cancer (EPIC-Norfolk): a prospective population study,”
Psychosomatic Medicine, vol. 69, no. 5, pp. 410–414, 2007.
[4] P. K. Myint, P. G. Surtees, N. W. J. Wainwright et al., “Physical
health-related quality of life predicts stroke in the EPIC-
Norfolk,” Neurology, vol. 69, no. 24, pp. 2243–2248, 2007.
[ 5 ]J .X i e ,E .Q .W u ,Z .J .Z h e n g ,P .W .S u l l i v a n ,L .Z h a n ,a n d
D. R. Labarthe, “Patient-reported health status in coronary
heart disease in the United States: age, sex, racial, and ethnic
diﬀerences,” Circulation, vol. 118, no. 5, pp. 491–497, 2008.
[ 6 ] J .X i e ,E .Q .W u ,Z .J .Z h e n ge ta l . ,“ I m p a c to fs tr o k eo nh e a l t h -
related quality of life in the noninstitutionalized population in
theUnitedStates,”Stroke, vol. 37, no. 10, pp.2567–2572, 2006.
[7] K. S. Hong, J. L. Saver, D. W. Kang et al., “Years of optimum
health lost due to complications after acute ischemic stroke:
disability-adjustedlife-yearsanalysis,”Stroke,vol.41,no .8,pp .
1758–1765, 2010.
[ 8 ]M .S .D h a m o o n ,Y .P .M o o n ,M .C .P a i ke ta l . ,“ Q u a l i t yo fl i f e
declines after ﬁrst ischemic stroke: the Northern Manhattan
Study,” Neurology, vol. 75, no. 4, pp. 328–334, 2010.
[9] J. C. Dumville, A. J. Lee, F. B. Smith, and F. G. R. Fowkes,
“The health-related quality of life of people with peripheral
arterial disease in the community: the Edinburgh Artery
Study,” British Journal of General Practice, vol. 54, no. 508, pp.
826–831, 2004.
[10] D. R. Liles, M. A. Kallen, L. A. Petersen, and R. L. Bush,
“Quality of life and peripheral arterial disease,” Journal of
Surgical Research, vol. 136, no. 2, pp. 294–301, 2006.
[11] F. Dick, V. Grob´ ety, F. F. Immer et al., “Outcome and quality
of life in patients treated for abdominal aortic aneurysms: a
single center experience,” World Journal of Surgery, vol. 32, no.
6, pp. 987–994, 2008.
[12] B. Aljabri, K. Al Wahaibi, D. Abner et al., “Patient-reported
quality of life after abdominal aortic aneurysm surgery: a
prospective comparison of endovascular and open repair,”
Journal of Vascular Surgery, vol. 44, no. 6, pp. 1182–e2, 2006.
[13] M. I. Geerlings, A. P. A. Appelman, K. L. Vincken et al.,
“Brain volumes and cerebrovascular lesions on MRI in
patients with atherosclerotic disease. The SMART-MR study,”
Atherosclerosis, vol. 210, no. 1, pp. 130–136, 2010.
[14] D. Inzitari, G. Pracucci, A. Poggesi et al., “Changes in white
matter as determinant of global functional decline in older
independent outpatients: three year follow-up of LADIS
(leukoaraiosis and disability) study cohort,” BMJ (Clinical
research ed.), vol. 339, p. b2477, 2009.
[15] J. C. De Groot, F. E. De Leeuw, M. Oudkerk, A. Hofman, J.
Jolles, and M. M. B. Breteler, “Cerebral white matter lesions
anddepressivesymptomsinelderlyadults,”Archives of General
Psychiatry, vol. 57, no. 11, pp. 1071–1076, 2000.
[16] A. Kumar, W. Bilker, Z. Jin, and J. Udupa, “Atrophy and
high intensity lesions: complementary neurobiological mech-
anisms in late-life major depression,” Neuropsychopharmacol-
ogy, vol. 22, no. 3, pp. 264–274, 2000.
[ 1 7 ]W .M .v a nd e rF l i e r ,E .C .W .v a nS t r a a t e n ,F .B a r k h o fe t
al., “Small vessel disease and general cognitive function in
nondisabled elderly: the LADIS study,” Stroke, vol. 36, no. 10,
pp. 2116–2120, 2005.8 Journal of Aging Research
[18] T. D. Vannorsdall, S. R. Waldstein, M. Kraut, G. D. Pearl-
son, and D. J. Schretlen, “White matter abnormalities and
cognition in a community sample,” Archives of Clinical Neu-
ropsychology, vol. 24, no. 3, pp. 209–217, 2009.
[19] N. D. Prins, E. J. van Dijk, T. den Heijer et al., “Cerebral small-
vessel disease and decline in information processing speed,
executive function and memory,” Brain, vol. 128, no. 9, pp.
2034–2041, 2005.
[20] O. Godin, C. Dufouil, P. Maillard et al., “White matter lesions
asapredictorofdepressionintheelderly:the3C-Dijonstudy,”
Biological Psychiatry, vol. 63, no. 7, pp. 663–669, 2008.
[21] R. D. Nebes, C. F. Reynolds, F. Boada et al., “Longitudinal
increaseinthevolumeofwhitematterhyperintensitiesinlate-
onsetdepression,”InternationalJournalofGeriatricPsychiatry,
vol. 17, no. 6, pp. 526–530, 2002.
[22] P.Anbeek,K.L.Vincken,M.J.P.vanOsch,R.H.C.Bisschops,
and J. van der Grond, “Probabilistic segmentation of white
matter lesions in MR imaging,” NeuroImage,v o l .2 1 ,n o .3 ,p p .
1037–1044, 2004.
[23] P. Anbeek, K. L. Vincken, G. S. van Bochove, M. J. P. van Osch,
and J. van der Grond, “Probabilistic segmentation of brain
tissue in MR imaging,” NeuroImage, vol. 27, no. 4, pp. 795–
804, 2005.
[24] J.E.Ware,M.Kosinski,andS.D.Keller,“A12-itemshort-form
health durvey: construction of scales and preliminary tests of
reliability and validity,” Medical Care, vol. 34, no. 3, pp. 220–
233, 1996.
[25] J. E. Ware Jr. and C. D. Sherbourne, “The MOS 36-item short-
form health survey (SF-36). I. Conceptual framework and
itemselection,”MedicalCare,vol.30,no.6,pp.473–483,1992.
[26] B. Gandek, J. E. Ware, N. K. Aaronson et al., “Cross-validation
of item selection and scoring for the SF-12 Health Survey in
nine countries: results from the IQOLA Project,” Journal of
Clinical Epidemiology, vol. 51, no. 11, pp. 1171–1178, 1998.
[27] “Second European Consensus document on chronic critical
leg ischemia,” Circulation, vol. 84, pp. IV1–IV26, 1991.
[ 2 8 ]J .C .v a nS w i e t e n ,P .J .K o u d s t a a l ,M .C .V i s s e r ,H .J .A .
Schouten, and J. van Gijn, “Interobserver agreement for the
assessment of handicap in stroke patients,” Stroke, vol. 19, no.
5, pp. 604–607, 1988.
[29] E. C. W. van Straaten, F. Fazekas, E. Rostrup et al., “Impact of
white matter hyperintensities scoring method on correlations
with clinical data: the LADIS study,” Stroke,v o l .3 7 ,n o .3 ,p p .
836–840, 2006.
[ 3 0 ]D .M .J .v a nd e nH e u v e l ,V .H .T e nD a m ,A .J .M .d eC r a e ne t
al., “Measuring longitudinal white matter changes: compari-
son of a visual rating scale with a volumetric measurement,”
American Journal of Neuroradiology, vol. 27, no. 4, pp. 875–
878, 2006.
[31] M. Yoshita, E. Fletcher, and C. DeCarli, “Current concepts of
analysis of cerebral white matter hyperintensities on magnetic
resonance imaging,” Topics in Magnetic Resonance Imaging,
vol. 16, no. 6, pp. 399–407, 2005.
[32] J. E. Ware Jr., B. Gandek, M. Kosinski et al., “The equivalence
of SF-36 summary health scores estimated using standard and
country-speciﬁc algorithms in 10 countries: results from the
IQOLA Project,” Journal of Clinical Epidemiology, vol. 51, no.
11, pp. 1167–1170, 1998.
[33] B. D. Thombs, E. B. Bass, D. E. Ford et al., “Prevalence of
depression in survivors of acute myocardial infarction: review
of the evidence,” Journal of General Internal Medicine, vol. 21,
no. 1, pp. 30–38, 2006.
[34] M. L. Hackett, C. Yapa, V. Parag, and C. S. Anderson, “Fre-
quency of depression after stroke: a systematic review of
observational studies,” Stroke, vol. 36, no. 6, pp. 1330–1340,
2005.
[35] D. K. Hayes, C. H. Denny, N. L. Keenan, J. B. Croft, and K.
J. Greenlund, “Health-related quality of life and hypertension
status, awareness, treatment, and control: National Health
and Nutrition Examination Survey, 2001–2004,” Journal of
Hypertension, vol. 26, no. 4, pp. 641–647, 2008.
[36] L.H.Kuller,K.L.Margolis,S.A.Gaussoinetal.,“Relationship
of hypertension, blood pressure, and blood pressure control
with white matter abnormalities in the Women’s Health
Initiative Memory Study (WHIMS)—MRI trial,” Journal of
Clinical Hypertension, vol. 12, no. 3, pp. 203–212, 2010.
[ 3 7 ]E .J .v a nD i j k ,N .D .P r i n s ,H .A .V r o o m a n ,A .H o f m a n ,P .
J. Koudstaal, and M. M. B. Breteler, “Progression of cerebral
small vessel disease in relation to risk factors and cognitive
consequences: rotterdam scan study,” Stroke, vol. 39, no. 10,
pp. 2712–2719, 2008.
[38] B. van Harten, J. M. Oosterman, B. J. Potter Van Loon,
P. Scheltens, and H. C. Weinstein, “Brain lesions on MRI
in elderly patients with type 2 diabetes mellitus,” European
Neurology, vol. 57, no. 2, pp. 70–74, 2007.
[39] L. Pantoni, “Pathophysiology of age-related cerebral white
matter changes,” Cerebrovascular Diseases,v o l .1 3 ,n o .2 ,p p .
7–10, 2002.
[ 4 0 ]G .S .A l e x o p o u l o s ,B .S .M e y e r s ,R .C .Y o u n g ,S .C a m p b e l l ,D .
Silbersweig, and M. Charlson, “‘Vascular depression’ hypothe-
sis,”ArchivesofGeneralPsychiatry,vol.54,no.10,pp.915–922,
1997.